Quantum-Mechanics Calculations Elucidate Skin-Sensitizing Pharmaceutical Compounds.

Autor: Kostal J; Designing Out Toxicity (DOT) Consulting LLC, 2121 Eisenhower Avenue, Alexandria, Virginia 22314, United States.; The George Washington University, 800 22nd St. NW, Washington, District of Columbia 20052, United States., Voutchkova-Kostal A; Designing Out Toxicity (DOT) Consulting LLC, 2121 Eisenhower Avenue, Alexandria, Virginia 22314, United States., Bercu JP; Gilead Sciences Inc. 333 Lakeside Drive, Foster City, California 94404, United States., Graham JC; Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, United States., Hillegass J; Bristol Myers Squibb, 1 Squibb Drive, New Brunswick, New Jersey 08901, United States., Masuda-Herrera M; Gilead Sciences Inc. 333 Lakeside Drive, Foster City, California 94404, United States., Trejo-Martin A; Gilead Sciences Inc. 333 Lakeside Drive, Foster City, California 94404, United States., Gould J; SafeBridge Regulatory & Life Sciences Group, 330 Seventh Ave #2001, New York, New York 10001, United States.

Publikováno v: Chemical research in toxicology [Chem Res Toxicol] 2024 Aug 19; Vol. 37 (8), pp. 1404-1414. Date of Electronic Publication: 2024 Jul 28.

In Silico Assessment of Biomolecule Reactivity with Leachables.

Autor: Johnson C; Instem, 1393 Dublin Road, Columbus, OH 43215; candice.johnson@instem.com., Kiehl D; Eli Lilly and Company, Indianapolis, IN 46285., Christiaens P; Nelson Labs, Romeinsestraat 12, 3001 Heverlee, Belgium., Jodar FS; Zymvol Biomodeling, Carrer Pau Claris, 94, 08010 Barcelona, Spain., Cuyvers R; Nelson Labs, Romeinsestraat 12, 3001 Heverlee, Belgium., Bassan A; Innovatune, Via Giulio Zanon 130/D, 35129 Padova, Italy., Beilke L; Toxicology Solutions, Inc., Marana, AZ 85658., Bercu JP; Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404., Costelloe T; IMIHGOM B.V., Galileiweg 8, 2333 BD Leiden, The Netherlands., Cross KP; Instem, 1393 Dublin Road, Columbus, OH 43215., Feilden A; BicycleTx Ltd, Cambridge CB21 6GS, United Kingdom., Filler R; Drug Development Consultants, LLC, StoneBridge Farm, 15 Elizabeth Lane, Bedminster, NJ 07921., Lucas MF; Zymvol Biomodeling, Carrer Pau Claris, 94, 08010 Barcelona, Spain., Masuda-Herrera MJ; Gilead Sciences, 333 Lakeside Drive, Foster City, CA 94404., Moghimi M; IMIHGOM B.V., Galileiweg 8, 2333 BD Leiden, The Netherlands., Morley N; Element Materials Technology, Manchester, M23 9BE, United Kingdom., Paskiet D; West Pharmaceutical Services, Inc., 530 Herman O. West Drive, Exton, PA 19341., Pavan M; Innovatune, Via Giulio Zanon 130/D, 35129 Padova, Italy., Pletz J; Exponent International Ltd., Nauenstrasse 67, 4052 Basel, Switzerland., Reddy MV; Merck & Co., Inc., West Point, PA 19486; and., Waine CJ; Bibra Toxicology Advice and Consulting, Wallington, Surrey, United Kingdom., Myatt GJ; Instem, 1393 Dublin Road, Columbus, OH 43215.

Publikováno v: PDA journal of pharmaceutical science and technology [PDA J Pharm Sci Technol] 2024 Jun 28; Vol. 78 (3), pp. 214-236. Date of Electronic Publication: 2024 Jun 28.

Acceptable intakes (AIs) for 11 small molecule N-nitrosamines (NAs).

Autor: Bercu JP; Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, CA, USA. Electronic address: joel.bercu@gilead.com., Masuda-Herrera M; Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, CA, USA., Trejo-Martin A; Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, CA, USA., Sura P; Gilead Sciences, Inc., Nonclinical Safety and Pathobiology (NSP), Foster City, CA, USA., Jolly R; Eli Lilly and Company, Indianapolis, IN, USA., Kenyon M; Pfizer Worldwide Research, Development and Medical, Drug Safety Research and Development, Groton, CT, USA., Thomas R; Lhasa Limited, Leeds, UK., Ponting DJ; Lhasa Limited, Leeds, UK., Snodin D; Xiphora Biopharma Consulting, Bristol, UK., Tuschl G; Merck KGaA, Global Chemical and Preclinical Safety, Darmstadt, Germany., Simon S; Merck KGaA, Global Chemical and Preclinical Safety, Darmstadt, Germany., De Vlieger K; Janssen Research & Development, Beerse, Antwerp, Belgium., Hutchinson R; Janssen Research & Development, Spring House, PA, USA., Czich A; Sanofi, R&D Preclinical Safety, Frankfurt, Germany., Glowienke S; Novartis AG, NIBR, Klybeckstrasse, Basel, Switzerland., Reddy MV; Merck Research Laboratories, West Point, PA, USA., Johanssen S; Bayer AG, Pharmaceuticals, Research & Development, Berlin, Germany., Vock E; Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach an der Riss, Germany., Claude N; Servier Paris-Saclay R&D Institute, Gif-sur-Yvette, France., Weaver RJ; Servier Paris-Saclay R&D Institute, Gif-sur-Yvette, France.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2023 Aug; Vol. 142, pp. 105415. Date of Electronic Publication: 2023 May 29.

Development of Duration-Based Non-Mutagenic Thresholds of Toxicological Concern (TTCs) Relevant to Parenteral Extractables and Leachables (E&Ls).

Autor: Masuda-Herrera MJ; Nonclinical Safety and Pathobiology (NSP), Gilead Sciences, Inc., Foster City, CA, USA; Melisa.Masuda-Herrera@gilead.com., Bercu JP; Nonclinical Safety and Pathobiology (NSP), Gilead Sciences, Inc., Foster City, CA, USA., Broschard TH; Merck Healthcare KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany., Burild A; Safety Sciences, Imaging and Data Management, Novo Nordisk A/S, Novo Nordisk Park 2760 Måløv, Denmark., Hasselgren C; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080., Parris P; Pfizer Worldwide Research and Development, Sandwich, United Kingdom., Ford LC; Department of Veterinary Integrative Biosciences, Interdisciplinary Faculty of Toxicology Program, Texas A&M University, 4466 TAMU, College Station, TX, 77843-4466., Graham J; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080., Stanard B; Ultragenyx Pharmaceutical Inc., Novato, CA., Comerford M; Pfizer Global Research & Development, Groton, CT, 06340., Lettiere D; Pfizer Global Research & Development, Groton, CT, 06340., Erler S; Wella Company, Berliner Allee 65, 64295 Darmstadt, Germany., Callis CM; Lilly Research Laboratories, Eli Lilly & Company, Indianapolis, IN., Morinello E; Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080., Muster W; Roche Pharmaceutical Research & Early Development, Pharmaceutical Sciences, Roche Innovation Center, Basel, Switzerland., Martin EA; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Griffin TR; Teva Branded Pharmaceutical Products R&D, Inc., West Chester, PA, 19380; and., Nagao L; Faegre Drinker Biddle & Reath LLP, Washington, DC., Cruz M; Faegre Drinker Biddle & Reath LLP, Washington, DC.

Publikováno v: PDA journal of pharmaceutical science and technology [PDA J Pharm Sci Technol] 2022 Sep-Oct; Vol. 76 (5), pp. 369-383. Date of Electronic Publication: 2022 Jan 14.

Harmonized 3Rs-based non-mutagenic impurity qualification study designs developed using the results of an IQ consortium survey.

Autor: Mitra MS; Genentech Inc, Safety Assessment, South San Francisco, CA, USA. Electronic address: mitram2@gene.com., Datta K; Bristol-Myers Squibb, Nonclinical Research and Development, NJ, USA., Hutchinson R; Janssen Research & Development, LLC, Spring House, PA, USA., Nicolette JJ; Abbvie, Inc., Pre-clinical Safety, North Chicago, IL, USA., Pettersen JC; Vertex Pharmaceuticals, Pre-clinical Safety Assessment Boston, MA, USA., Wegesser TC; Amgen, Translational Safety and Bioanalytical Sciences, Thousand Oaks, CA, USA., Bercu JP; Gilead Sciences, Nonclinical Safety and Pathobiology, Foster City, CA, USA.

Publikováno v: Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2021 Jun; Vol. 122, pp. 104895. Date of Electronic Publication: 2021 Feb 19.